TY - JOUR
T1 - Genomic signatures predict the immunogenicity of BRCA-deficient breast cancer
AU - Kraya, Adam A.
AU - Maxwell, Kara N.
AU - Wubbenhorst, Bradley
AU - Wenz, Brandon M.
AU - Pluta, John
AU - Rech, Andrew J.
AU - Dorfman, Liza M.
AU - Lunceford, Nicole
AU - Barrett, Amanda
AU - Mitra, Nandita
AU - Morrissette, Jennifer J.D.
AU - Feldman, Michael
AU - Nayak, Anupma
AU - Domchek, Susan M.
AU - Vonderheide, Robert H.
AU - Nathanson, Katherine L.
N1 - Funding Information:
J.J.D. Morrissette reports receiving speakers bureau honoraria from TriCon and CHI NHS Summit, and is a consultant/advisory board member for Novartis and Loxo. S.M. Domchek reports receiving speakers bureau honoraria from AstraZeneca, Clovis, and Bristol-Myers Squibb. R.H. Vonderheide reports receiving speakers bureau honoraria from Celgene and Janssen, is a consultant/advisory board member for Apexigen, AstraZeneca, Genentech, Lilly, MedImmune, Merck, and Verastem, and reports receiving commercial research grants from Apexigen, Fibrogen, Inovio, Janssen, and Lilly. No potential conflicts of interest were disclosed by the other authors.
Funding Information:
The authors thank the patients that participated in their studies. The authors further thank E. John Wherry, PhD (University of Pennsylvania), for helpful comments on the manuscript. Financial support for this work was provided by the National Institutes of Health (P30 CA016520), Basser Center for BRCA at the University of Pennsylvania (to K.L. Nathanson, S.M. Domchek, and R.H. Vonderheide), Breast Cancer Research Foundation (to K.L. Nathanson, S.M. Domchek, and R.H. Vonderheide), Susan G. Komen Foundation (to S.M. Domchek), Rooney Family Foundation (to K.L. Nathanson and S.M. Domchek), National Institutes of Health (K12-CA076931; to K.N. Maxwell), Konner Family Foundation (to K.N. Maxwell), Parker Institute for Cancer Immunotherapy (to R.H. Vonderheide, A.J. Rech, and K.L. Nathanson), National Center for Advancing Translational Sciences of the National Institutes of Health (TL1TR001880; to A.A. Kraya), and National Human Genome Research Institute of the National Institutes of Health (5T32HG009495-02; to A.A. Kraya).
Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2019
Y1 - 2019
N2 - Purpose: Breast cancers with BRCA1/2 alterations have a in BRCA1/2 mutant breast cancers. Further, absence of relatively high mutational load, suggesting that immune allele-specific loss of heterozygosity (LOH negative; P ¼ checkpoint blockade may be a potential treatment option. 0.01) or subclonality (P ¼ 0.003) of germline and somatic However, the degree of immune cell infiltration varies widely, BRCA1/2 mutations, respectively, predicted for heightened and molecular features contributing to this variability remain cytolytic activity. Gene set analysis found that multiple unknown. innate and adaptive immune pathways that converge on Experimental Design: We hypothesized that genomic sig-NF-kB may contribute to this heightened immunogenicity. natures might predict immunogenicity in BRCA1/2 breast IHC of Penn breast cancers demonstrated increased CD45þ cancers. Using The Cancer Genome Atlas (TCGA) genomic (P ¼ 0.039) and CD8þ infiltrates (P ¼ 0.037) and increased data, we compared breast cancers with (89) and without (770) PDL1 expression (P ¼ 0.012) in HRD-low or LOH-negative either germline or somatic BRCA1/2 alterations. We also cancers. Triple-negative cancers with low HRD had far studied 35 breast cancers with germline BRCA1/2 mutations greater CD8þ T cells (P ¼ 0.0011) and Perforin 1 expression from Penn using WES and IHC. (P ¼ 0.014) compared with hormone receptor-positive Results: We found that homologous recombination defi-HRD-high cancers. ciency (HRD) scores were negatively associated with expression-Conclusions: HRD scores and hormone receptor subtype based immune indices [cytolytic index (P ¼ 0.04), immune are predictive of immunogenicity in BRCA1/2 breast cancers ESTIMATE (P ¼ 0.002), type II IFN signaling (P ¼ 0.002)] despite and may inform the design of optimal immune therapeutic being associated with a higher mutational/neoantigen burden, strategies.
AB - Purpose: Breast cancers with BRCA1/2 alterations have a in BRCA1/2 mutant breast cancers. Further, absence of relatively high mutational load, suggesting that immune allele-specific loss of heterozygosity (LOH negative; P ¼ checkpoint blockade may be a potential treatment option. 0.01) or subclonality (P ¼ 0.003) of germline and somatic However, the degree of immune cell infiltration varies widely, BRCA1/2 mutations, respectively, predicted for heightened and molecular features contributing to this variability remain cytolytic activity. Gene set analysis found that multiple unknown. innate and adaptive immune pathways that converge on Experimental Design: We hypothesized that genomic sig-NF-kB may contribute to this heightened immunogenicity. natures might predict immunogenicity in BRCA1/2 breast IHC of Penn breast cancers demonstrated increased CD45þ cancers. Using The Cancer Genome Atlas (TCGA) genomic (P ¼ 0.039) and CD8þ infiltrates (P ¼ 0.037) and increased data, we compared breast cancers with (89) and without (770) PDL1 expression (P ¼ 0.012) in HRD-low or LOH-negative either germline or somatic BRCA1/2 alterations. We also cancers. Triple-negative cancers with low HRD had far studied 35 breast cancers with germline BRCA1/2 mutations greater CD8þ T cells (P ¼ 0.0011) and Perforin 1 expression from Penn using WES and IHC. (P ¼ 0.014) compared with hormone receptor-positive Results: We found that homologous recombination defi-HRD-high cancers. ciency (HRD) scores were negatively associated with expression-Conclusions: HRD scores and hormone receptor subtype based immune indices [cytolytic index (P ¼ 0.04), immune are predictive of immunogenicity in BRCA1/2 breast cancers ESTIMATE (P ¼ 0.002), type II IFN signaling (P ¼ 0.002)] despite and may inform the design of optimal immune therapeutic being associated with a higher mutational/neoantigen burden, strategies.
UR - http://www.scopus.com/inward/record.url?scp=85068757493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068757493&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-18-0468
DO - 10.1158/1078-0432.CCR-18-0468
M3 - Article
C2 - 30914433
AN - SCOPUS:85068757493
SN - 1078-0432
VL - 25
SP - 4363
EP - 4374
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 14
ER -